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Emergency arising from patients' fear of taking 
antimalarials during these COVID-19 times: are 
antimalarials as unsafe for cardiovascular 
health as recent reports suggest?
We read with interest the paper of Graef et al recently published 
in your journal about the situation resulting from the massive 
use of antimalarials for severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2/COVID-19), despite the fact that 
the evidence is controversial and there are concerns about its 
possible cardiotoxicity, leaving rheumatic patients who use them 
in a position of vulnerability due to medication shortages.1 In 
the past few weeks, several papers have been published about the 
efficacy and safety of the antimalarials chloroquine (CLQ) and 
hydroxychloroquine (HCLQ) for the treatment of the different 
phases of infection by SARS- CoV-2/COVID-19, and the data are 
controversial. However, it is striking that some studies report 
high rates of cardiovascular events (CVEs) associated mainly 
with cardiac arrhythmias.2 .
These findings of adverse CVEs reported in the aforemen-
tioned studies have unfortunately led to the emergency in this 
group of patients around fear of chronic use of antimalarials, 
and many users are abandoning these medications, which implies 
great clinical risk due to relapses that may appear.3 On the 
other hand, the massive use of antimalarials for COVID-19 has 
resulted in medication shortages in some settings with potential 
consequences to patients users.
Antimalarials have been used for several decades for the treat-
ment of malaria and some autoimmune diseases, mainly rheuma-
toid arthritis (RA) and lupus, with great utility and efficacy, and 
also great safety at conventional doses (250 mg per day of CLQ 
and 200–400 mg per day of HCLQ).4
We show a real- life experience in a rheumatic centre in 
Bogota, Colombia. We performed a retrospective cohort anal-
ysis of adverse events (AEs), adverse reactions (ARs) and 
medication- related problems (MRPs) presented in the last 16 
months, according to the methodology of the Third Consensus 
of Granada. The severity of the events and reactions was eval-
uated using the Dader Method of therapeutic drug monitoring, 
and the Naranjo algorithm was used to characterise them as AEs, 
ARs or MRPs.
Here, we report the outcomes since 1 January 2019–30 April 
2020. By the end of 2018, there were 1004 patients with RA 
using antimalarials; currently, there are 660 patients still using 
CLQ/HCLQ; 583 (88.3%) are using CLQ and 77 (11.7%) are 
using HCLQ; of them, 186 (28.2%) patients have cardiovascular 
comorbidities, previous to antimalarial use, like primary hyper-
tension, cardiovascular disease or the two combined (table 1).
Regarding safety concerns during observation period, 
344 patients presented with AEs and ARs that required the 
withdrawal of antimalarials; of them, 130 (37.9%) had retinal 
toxicity an expected AR; 103 (30%) had gastrointestinal intol-
erance, accepted as an AE; 110 (31.8%) had different types of 
dermatological ARs; 1 patient had severe dizziness, possibly an 
MRP; and there were no CVEs or arrhythmias, despite the fact 
that 95 (27.6%) patients previously had cardiovascular comor-
bidity (table 2).
At first glance, these results seem surprising; there are zero 
incidences of new, incidental CVE in this RA cohort using anti-
malarials, although of course, we are talking about different 
doses for RA and COVID-19; on the contrary, CLQ and HCLQ 
have been associated with a reduced risk of CVE in patients with 
rheumatic diseases through robust research,5 in addition to the 
finding that the use of HCLQ is independently associated with 
decreased risk for cardiovascular morbidity among patients with 
RA.6 AEs and ARs presented by these patients are consistent 
with data previously published but reinforce the fact that anti-
malarials are drugs that lack cardiotoxicity in rheumatic patients; 
therefore, education for doctors and patients in general must 
be reinforced to prevent antimalarials from being abandoned 
because of the past news.
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Table 1 Cardiovascular disease in patients with rheumatoid arthritis currently and previously using antimalarials
Currently users of antimalarials Previous users of antimalarials withdrawn by adverse events
Comorbidities
CLQ
(n=583) HCLQ (n=77) Total n=660 (%)
CLQ
(n=330) HCLQ (n=14) Total n=344 (%)
PH 140 16 156 (23.5) 74 1 75 (21.8)
CVD 10 4 14 (2.1) 3 0 3 (0.9)
PH and CVD 15 1 16 (2.4) 16 1 17 (4.9)
No CVD/PH comorbidities 418 56 474 (72.0) 237 12 249 (72.4)
CLQ, chloroquine; CVD, cardiovascular disease; HCLQ, hydroxychloroquine;PH, primary hypertension.
Table 2 Adverse events and reactions to antimalarials in patients 











Retinal toxicity 100 30 130 (37.9)
Gastrointestinal AEs 83 20 103 (30.0)
Dermatological ARs 65 45 110 (31.8)
Severe dizziness 1 0 1 (0.3)
CVD AEs/ARs 0 0 0 (0.0)
AE, adverse event; AR, adverse reaction; CVD, cardiovascular disease; PH, primary 
hypertension.
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